GlobeNewswire Inc | Jan 4, 2021 07:05AM EST

January 04, 2021

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the companys transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021.

Mr. Diaz will focus on key opportunities to fulfill the companys mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the companys genetic insights. The presentation will be available via a live audio webcast accessible at the following directlinkor through the investor information section of Myriads website at www.myriad.com.

About Myriad Genetics

Myriad Genetics Inc., is a leading precision medicine company dedicated improving and transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across in specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact: Investor Contact:Jared Maxwell Scott Gleason(801) 505-5027 (801) 584-1143jmaxwell@myriad.com sgleason@myriad.com